GLG News by Physicians who Treat Hypercholesterolemia in the U.S.

It is important to understand that geographic placement of these clinics is important.  I think these clinics will continue to pop up until the industry feels out exactly where the market is.  We are located in the southwest suburbs of Chicago, and there are many of these clinics which are...

The time taken away from seeing patients is expensive.  The physicians do not feel like they are trained well enough in understanding scientific studies and so they may be biased by information provided by the representatives that is not scientific.  They believe that innovations by pharmaceutical...

I anticipate vytorin and zetia sales will be down substantial when the IMS numbers come out tommorrow, but that this will be only the beginning of a negative trend for these scripts. I list below several reasons why.

TRITON-TIMI 38 study of 13,608 patients with ACS compared prasugrel against clopidogrel, combined with aspirin.  Prasugrel reduced the combined rate of CV death, MI or stroke (12.1% for clopidogrel vs. 9.9% for prasugrel). The benefit came at a cost of increased serious bleeding (1.4%, vs....

It is disappointing that Medicare does not pay for well exams where vaccines like this would be given.  It is unfortunate that in an attempt by medicare to save money, they are probably losing money.  It is at the annual well exam where I counsel patients on the vaccinations that they should...

I work as both an ER physician and a Family Physician in a clinic and something needs to be done so that I do not need to see patients in the ER for problems that could easily be handled in the less expensive clinic.  Other countries have better health plans because patients have an incentive to...

One, twenty years ago I was the chairman of the government affairs committee of the American Society for Clinical Pharmacology and Therapeutics; under that role my committee was successful lobbying for approval new investigational drugs for possible treatment of AIDS. We were successful in getting the...

A new idea - I don't think so Trust Blue Cross??????

The announcement the new trial comparing Lipitor to Crestor  is interesting but not unexpected.  It is timed to end near the end of lipitor's patent. A win- which is likely- will certainly help AZN sell their drug against the much cheaper generic lipitor.

Impressive data on Ranexa in HGBA1c. The result of a decrease of 0.64 vs baseline and 0.43 vs placebo are at first glance underwhelming.  But a closer looks shows that the results are realy quite impressive